


Clinical Pathology And Cancer Epidemiology 2020

Dr. AK Aravind Kumar

MARKET ANALYSIS

The Worldwide market on pathology is surveyed to be \$191.00 million out of 2012 and prepared to create a CAGR of 12% to reach \$336.61 million by 2017.

This report shows the <u>pathology</u> graph over the time of 2013 to 2018. The business part was surveyed to be \$250.2 million of every 2013 and it depends upon to reach \$437 million by 2018, creating at CAGR of 11.8% from 2013 to 2018. This report covers the depiction, and gauge of the mechanized pathology showcase with respect to things and applications. In respective of things, the pathology showcase contains scanners, examination, accumulating, and correspondence. The business division is divided into human and animal pathology. Pathology of Human is divided into pharmaceutical and biological associations, offices for specialist's and reference labs, planning and preparing centres, while animal pathology is partitioned into pharmaceutical and biotechnology associations, investigated affiliations, and insightful and government look into establishments.



A glimpse of the major drivers and restraints affecting the pathology market is mentioned below

Drivers:

- Rise in the <u>adoption of pathology</u> to enhance lab efficiency
- Increasing application of pathology in drug development and companion diagnostics
- Ease of consultation enabled by pathology
- Growing initiatives by governments and industry players
- Growing number of research projects establishing the efficacy of pathology

Restraints:

- Higher cost of <u>pathology systems</u>
- Regulatory concerns
- Dearth in <u>standard guidelines</u>

Pathology research institutes in Europe continent

- France
- Rest of Europe

The global digital pathology market, valued at \$1.98 billion in 2012, is estimated to reach \$5.7 billion by 2020. The In vitro diagnostics market revenue is expected to reach \$74.65 billion by 2020, from the market value of \$53.32 billion in 2013, at a CAGR of 5.34% during 2014-2020. Diagnostic Medicine has \$35 billion market, growth 5-7% yearly. Pathology labs will take approximately \$15-16 billion in revenue, and they will spend roughly 12% of their revenues with their suppliers all over USA.

Overall Statistics


- Over 7000 licenses have been issued to pathology labs in the US
 - 1. 1,600-1,700 commercial labs
 - 2. 3,300-3,400 hospital labs
 - 3. 1,800-1,900 physicians' office labs
- Academic department in U.S. (130 medical schools; 155 training programs)
- 59 Universities are there in USA
- 36 Societies and Association

MARKET ANALYSIS OF CANCER

Pathology market study

Global Pathology/Cancer Drugs Market is expected to garner \$111.9 billion by 2020, registering a CAGR of 7.1% during the forecast period 2014 to 2020. Recent progress in biological therapies has widened the scale of therapeutic targets for treatment of cancer with the identification of tumor cell specific genes. Immunotherapies/ biologics are emerging as potential therapies to find the permanent cure for various cancer types. Amongst various biologics, drugs based on monoclonal antibodies (mAbs) have gained significant attention in recent years due to their high efficacy.

Global cancer drugs market accounted for \$78,238.9 million in 2015. The cancer drugs market is driven by the growing prevalence of various types of cancer, increasing demand of biological and targeted drug therapies, continuous patent expiry of key cancer drugs and the rising impact of biosimilars. However, the high cost of drug development, the threat of failure and the adverse effects of cancer drug therapy, particularly chemotherapy, hinders the market growth. Developed nations have implemented strict regulations for the design and development of cancer drugs. USFDA and European Union have undertaken significant initiatives to fuel the growth of the cancer drugs market by providing premarket approval for potential drugs under clinical development. Asia-Pacific and LAMEA are promising regions for conducting clinical trials due a large population base and the low cost of clinical trials as compared to North America and Europe. Nevertheless, advancement of cancer drug research owing to biological/targeted therapies and personalized medicines hold promising opportunities for pharmaceutical, bio-pharmaceutical and



Worldwide pathology statistical surveying report gives point by point data about the business in light of the income (USD MN) for the estimate time frame. The examination study is a spellbinding investigation of this market underscoring the market drivers and restrictions that administer the general market development. The patterns and future prospects for the market are likewise incorporated into the report which gives a scholarly comprehension of the pathology business. Besides, the report measures the piece of the overall industry held by the real players of the business and gives a top to bottom perspective of the aggressive scene. This market is characterized into various fragments with point by point investigation of each regarding geology for the review time frame.

- Global Market on Pathology
- The Global Pathology Market is assessed to be \$191.00 million in 2012, and is ready to develop at a CAGR of 12% to reach \$336.61 million by 2017.

This report thinks about the worldwide computerized pathology market over the conjecture time of 2013 to 2018. The business sector was assessed at \$250.2 million in 2013 and is relied upon to reach \$437 million by 2018, developing at a CAGR of 11.8% from 2013 to 2018. This report covers the definition, portrayal, and estimate of the computerized pathology market regarding items and applications. In view of items, the computerized pathology market contains scanners, investigation, stockpiling, and correspondence. The application business sector is sorted into human and creature pathology. Human pathology is sectioned into pharmaceutical and biotech organizations, doctor's facilities and reference labs, and preparing and training focuses, while creature pathology is portioned into pharmaceutical and biotechnology organizations, contract research associations and scholarly and government research foundations.

Dr. AK Aravind Kumar, Head and Professor, IIT Bombay, India, Email: rsrivasta@iitb.ac.in